Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
BioAge Labs, Inc (BIOA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: BIOA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $
1 Year Target Price $
| 0 | Strong Buy |
| 0 | Buy |
| 3 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -7.19% | Avg. Invested days 16 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 674.12M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 2.88 - 26.62 | Updated Date 05/15/2025 |
52 Weeks Range 2.88 - 26.62 | Updated Date 05/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.4 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 539045726 | Price to Sales(TTM) - |
Enterprise Value 539045726 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 34167200 | Shares Floating 1177831 |
Shares Outstanding 34167200 | Shares Floating 1177831 | ||
Percent Insiders 3.8 | Percent Institutions 32.64 |
Analyst Ratings
Rating 2.5 | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 3 | Sell - | Strong Sell 1 | |
Strong Sell 1 |
Upturn AI SWOT
BioAge Labs, Inc
Company Overview
History and Background
BioAge Labs, Inc. is a privately held biotechnology company focused on developing therapies to extend healthy lifespan by targeting the molecular causes of aging. Founded in 2015, BioAge utilizes human aging data to identify and validate drug targets.
Core Business Areas
- Drug Discovery and Development: BioAge identifies drug targets by analyzing longitudinal human datasets, focusing on age-related diseases and pathways.
- Clinical Trials: BioAge conducts clinical trials to evaluate the safety and efficacy of their drug candidates.
- Data Analytics: Leveraging proprietary data analytics to identify and prioritize therapeutic interventions.
Leadership and Structure
The company is led by CEO Kristen Fortney, PhD. The organizational structure includes research and development, clinical operations, and business development teams.
Top Products and Market Share
Key Offerings
- BGE-105 (Azelaprag)uff1a: A PI3Ku03b4 inhibitor in Phase 2 clinical trials for COVID-19 and potentially extending healthy lifespan. Currently, the company doesn't have any public market share. Some competitors for PI3K inhibitors includes Verastem (VSTM) and Secura Bio.
- BGE-1750 (apilimod): An AP-1 inhibitor being evaluated for the treatment of cancer and aging-related conditions. The company doesn't have any public market share. Several companies developing cancer therapies, including Novartis (NVS) and Roche (RHHBY), could be seen as competitors.
Market Dynamics
Industry Overview
The biopharmaceutical industry focused on aging and longevity is growing rapidly, driven by increasing interest in extending healthy lifespan and treating age-related diseases. The market is characterized by intense research and development, regulatory hurdles, and high capital requirements.
Positioning
BioAge is positioned as a leader in utilizing human aging data to discover and develop novel therapies. Its competitive advantage lies in its proprietary data analytics platform and focus on validated targets.
Total Addressable Market (TAM)
The global market for anti-aging products and services is projected to reach hundreds of billions of dollars, offering substantial growth potential for BioAge. The company's focus on developing disease-modifying therapies for aging positions it well within this large TAM.
Upturn SWOT Analysis
Strengths
- Proprietary human aging data platform
- Experienced management team
- Strong intellectual property portfolio
- Clinical-stage pipeline
Weaknesses
- Limited financial resources as a private company
- Dependence on clinical trial outcomes
- Regulatory risks
- High R&D costs
Opportunities
- Partnerships with pharmaceutical companies
- Expansion of pipeline through new target identification
- Favorable regulatory changes
- Increasing investor interest in longevity therapeutics
Threats
- Competition from larger pharmaceutical companies
- Clinical trial failures
- Unexpected adverse events
- Changes in regulatory landscape
Competitors and Market Share
Key Competitors
- Unity Biotechnology (UBX)
- AgeX Therapeutics (AGE)
- Lineage Cell Therapeutics (LCTX)
Competitive Landscape
BioAge competes with other biotechnology companies focused on aging and longevity. Its competitive advantage lies in its data-driven approach, but it faces challenges from larger, more established companies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is difficult to assess without public financial data, but the company has advanced multiple programs into clinical trials.
Future Projections: Future growth depends on clinical trial outcomes, regulatory approvals, and strategic partnerships.
Recent Initiatives: Recent initiatives include advancing clinical trials for BGE-105 and BGE-1750, securing funding rounds, and expanding collaborations.
Summary
BioAge Labs is a promising biotechnology company focused on extending healthy lifespan using a data-driven approach. Its clinical-stage pipeline and experienced team are strengths, but its private status and dependence on clinical trial outcomes present risks. The aging therapeutics market is growing, presenting significant opportunities for BioAge if they can successfully navigate regulatory hurdles and secure partnerships. Bioage needs to keep an eye on the larger players and the competitive field as a whole as well as focus on the results of its clinical trials.
Peer Comparison
Sources and Disclaimers
Data Sources:
- BioAge Labs, Inc. website
- Publicly available information on clinical trials
- Industry reports on the biopharmaceutical market
Disclaimers:
This analysis is based on publicly available information and may not reflect all relevant factors. The biopharmaceutical industry is subject to significant risks and uncertainties. Market share data is based on limited information and may not be accurate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BioAge Labs, Inc
Exchange NASDAQ | Headquaters Richmond, CA, United States | ||
IPO Launch date 2024-09-26 | Co-Founder, CEO, President, Treasurer, Secretary & Director Dr. Kristen Fortney Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 62 | Website https://bioagelabs.com |
Full time employees 62 | Website https://bioagelabs.com | ||
BioAge Labs, Inc. is a biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It develops BGE-102, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.